Evidence guide · South Africa
Vitamin D after a heart attack: what the TARGET-D trial does and does not show
TARGET-D tailored vitamin D3 doses after a heart attack and was billed as halving heart attack risk. Its primary endpoint was not significant. What the trial found, why the heart attack result is secondary, and how it fits with VITAL and D-Health.
Review type: research summary. This page summarises published research and product labels, cited below.
"Heart attack risk halved" was the headline when the TARGET-D trial was presented at the American Heart Association's Scientific Sessions in November 2025. The peer-reviewed paper, published online in the European Heart Journal on 7 September 2026, reaches a plainer conclusion: tailoring vitamin D3 doses to push blood levels above 40 ng/mL after a heart attack "did not significantly reduce major adverse CV events". On 14 November 2026 the journal published a letter from researchers in Austria titled "TARGET-D: vitamin D thresholds and assumptions about cardiovascular benefit", and the journal's editorial on the trial is titled "More is not always better".
Short answer: TARGET-D missed its primary endpoint. The halving of heart attacks was a secondary result in a small, open-label trial, and it sits against large placebo-controlled trials that found no cardiovascular benefit from vitamin D. It is a reason for a bigger trial, not a reason to start high-dose vitamin D after a heart attack without your cardiologist.
What the trial did
TARGET-D was a pragmatic randomised trial run by Intermountain Health in Utah. Adults who had undergone angiography for a heart attack within the previous month, and who were taking less than 1,000 IU of vitamin D a day, were randomised between April 2017 and May 2023 to usual care or to targeted vitamin D management. The 630 participants in the published analysis had a median age of 63 and 78.1% were men; the American Heart Association's release says about 90% self-identified as white. Average follow-up was 4.2 years.
In the treatment group, vitamin D3 doses were adjusted with a dosing algorithm to reach and keep blood 25-hydroxyvitamin D, the standard vitamin D test, at a target of more than 40 ng/mL and up to 80 ng/mL (100 to 200 nmol/L). The trial registration describes the steps: if a level was below 40 ng/mL, the dose was started or increased and the level rechecked in three months, with the dose doubled if it was still below target; once above target, testing moved to once a year. The release says doses were reduced or stopped above 80 ng/mL and that calcium was monitored to guard against toxicity. The usual-care group had a baseline test and no vitamin D management, and the registration lists the trial as having no masking, so neither participants nor doctors were blinded and there was no placebo.
At the start, the median level was 25 ng/mL and 87.0% of participants were at or below 40 ng/mL. The paper says 52.4% began vitamin D3 at 5,000 IU a day. The release describes the same figure in two ways, once as the share who began on 5,000 IU and once as the share who "required more than 5,000 IU"; the peer-reviewed paper is the one to rely on.
What it found
- Primary endpoint: major adverse cardiovascular events (death, heart attack, heart failure hospitalisation and stroke combined) occurred in 15.7% with targeted vitamin D and 18.4% with usual care. The hazard ratio was 0.85 with a 95% confidence interval of 0.58 to 1.24 (P = 0.40), which is not statistically significant.
- Heart attack: 3.8% v 7.9% (hazard ratio 0.48, P = 0.03). This is the figure behind the "halved" headline.
- Death: 8.9% v 9.2% (hazard ratio 0.98, P = 0.95).
- Heart failure hospitalisation: 4.2% v 3.5% (hazard ratio 1.21, P = 0.65).
- Stroke: 1.6% v 0.9% (hazard ratio 1.69, P = 0.47).
The authors' conclusion is that targeted supplementation "did not significantly reduce major adverse CV events". When a trial's primary endpoint is not significant, a single positive secondary endpoint is usually treated as a finding to test again, not as proof. The other secondary endpoints did not move in the same direction: heart failure hospitalisations and strokes were slightly more common with vitamin D, though neither difference was significant.
Why the design matters
- Size: follow-up ended once at least 104 primary outcome events had occurred. With small numbers of events in each secondary category, percentages can swing on a handful of cases.
- No placebo and no blinding: the treatment group had repeat blood tests and dose reviews, while usual care had no planned contact beyond a baseline and end-of-study test, according to the registration. Extra attention can change how people are looked after in other ways.
- Who was studied: people who had just had a heart attack, mostly men and mostly white, in one health system. The AHA release notes that the results may not apply to people without heart disease.
- Target range: the trial aimed for more than 40 ng/mL and up to 80 ng/mL. The US Food and Nutrition Board, cited by the NIH Office of Dietary Supplements, considers 20 ng/mL (50 nmol/L) or more sufficient for most people and notes that levels above 50 ng/mL (125 nmol/L) can be associated with adverse effects. The trial's upper bound of 80 ng/mL is above that 50 ng/mL level. The American Heart Association release says doses were reduced or stopped above 80 ng/mL and that calcium was monitored to guard against toxicity.
How it fits with the bigger trials
Earlier trials gave everyone the same dose rather than adjusting it to a blood level, and the TARGET-D paper says that fixed, non-targeted dosing may be why they showed no clear reduction. Those trials are far larger. In VITAL, 25,871 US adults took 2,000 IU a day or placebo for a median of 5.3 years, and vitamin D did not lower major cardiovascular events (hazard ratio 0.97) or heart attacks (0.96). In New Zealand's ViDA trial, 5,108 adults analysed took 100,000 IU a month after a 200,000 IU first dose, with no effect on cardiovascular disease (hazard ratio 1.02), including in those who started deficient. A 2019 meta-analysis of 21 randomised trials and 83,291 people found no reduction in major cardiovascular events (relative risk 1.00) or heart attacks (1.00), with results generally consistent across baseline vitamin D level and dose.
The Australian D-Health trial is the closest to a positive signal. Among 21,315 people aged 60 to 84 given 60,000 IU a month or placebo for up to five years, major cardiovascular events were slightly less common with vitamin D (hazard ratio 0.91, 95% confidence interval 0.81 to 1.01), and heart attacks were lower (0.81, 0.67 to 0.98). The authors wrote that the absolute risk difference was small and the confidence interval was consistent with a null finding, and estimated that 172 people would need to take vitamin D to avoid one major cardiovascular event.
For people without an established reason for vitamin D treatment or testing, the Endocrine Society's 2024 guideline suggests against routine 25-hydroxyvitamin D testing and against empiric supplementation above the dietary reference intakes in healthy adults under 75. Empiric supplementation means a dose above those intakes without a 25-hydroxyvitamin D test. The guideline says there was no clear evidence defining an optimal target level for disease prevention in the populations it covers, and its advice does not apply to people with an established indication for vitamin D treatment or testing. TARGET-D asked a different question, in people who had just had a heart attack: whether aiming for a level above 40 ng/mL would reduce major cardiovascular events.
Our view
- The headline and the paper say different things. The paper's main result is null; the halving of heart attacks is a secondary finding from a trial of 630 people.
- Large placebo-controlled trials have not shown cardiovascular benefit from vitamin D, and TARGET-D does not overturn them. It raises a fair question about targeted dosing after a heart attack that needs a larger, blinded trial.
- Correcting a low level is a separate matter from heart disease. The NIH Office of Dietary Supplements says vitamin D is needed for bone growth, that deficiency can lead to rickets in children and osteomalacia in adults, and that inadequate levels can cause muscle weakness. A doctor can check the level and set the dose.
- The doses used in TARGET-D often started at 5,000 IU a day, above the 4,000 IU (100 micrograms) adult upper limit used in the UK and US, and were managed with repeat blood and calcium tests. That is not the same as buying a high-strength supplement and taking it unsupervised.
- Vitamin D supplements are not a substitute for the medicines and cardiac rehabilitation prescribed after a heart attack. Anyone who has had a heart attack, takes heart or blood pressure medicines, has kidney disease or high calcium, or is pregnant should speak to their cardiologist, doctor or pharmacist before changing their vitamin D.
South African rules
In South Africa, health supplements are regulated by SAHPRA as complementary medicines under the Medicines and Related Substances Act 101 of 1965, and SAHPRA publishes guidance on the safety and efficacy of health supplements. SAHPRA's complementary-medicines page limits health supplements to low-risk indications, such as general health maintenance, without reference to a specific disease. A vitamin D product sold with a claim to prevent heart attacks is not supported by the evidence above.
FAQ
Does vitamin D prevent a second heart attack?
It has not been shown to. In TARGET-D, heart attacks were less common with targeted vitamin D (3.8% v 7.9%), but that was a secondary result, and the trial's primary endpoint of major cardiovascular events was not significantly reduced. A larger blinded trial would be needed to confirm it.
What blood level did TARGET-D aim for?
More than 40 ng/mL and up to 80 ng/mL, which is 100 to 200 nmol/L. The median starting level was 25 ng/mL. The NIH Office of Dietary Supplements notes that levels above 50 ng/mL (125 nmol/L) can be associated with adverse effects. The trial's target went up to 80 ng/mL. The American Heart Association release says the treatment group had vitamin D and calcium levels monitored, and that doses were reduced or stopped above 80 ng/mL.
Is 5,000 IU of vitamin D a day safe?
It is above the 4,000 IU (100 micrograms) a day that UK and US guidance gives as the upper limit for adults. In TARGET-D, doses at that level were managed by clinicians with repeat blood and calcium tests. Too much vitamin D over a long period can raise calcium levels, which can damage the kidneys and heart. Follow your doctor's advice if they recommend a different dose.
Sources
These are the documents this page relies on.
- Targeted vitamin D supplementation and major adverse cardiovascular events after myocardial infarction: the TARGET-D trial. Eur Heart J. 2026 (online 7 September 2026), ehag611European Heart Journal (PubMed 42702500)
- More is not always better: vitamin D supplementation post-myocardial infarction in the Target-D trial. Eur Heart J. 2026 (online 7 September 2026), ehag672European Heart Journal (PubMed 42702499)
- TARGET-D: vitamin D thresholds and assumptions about cardiovascular benefit. Eur Heart J. 2026 (online 14 November 2026), ehag909European Heart Journal (PubMed 43031394)
- A Trial Evaluating Vitamin D Normalization on Major Adverse Cardiovascular-Related Events Among Myocardial Infarction Patients (The TARGET-D Study), NCT02996721ClinicalTrials.gov
- Heart attack risk halved in adults with heart disease taking tailored vitamin D doses (news release, 9 November 2025)American Heart Association
- Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease (VITAL). N Engl J Med. 2019;380(1):33-44New England Journal of Medicine (PubMed 30415629)
- Vitamin D supplementation and major cardiovascular events: D-Health randomised controlled trial. BMJ. 2023;381:e075230BMJ (PubMed 37380191)
- Effect of Monthly High-Dose Vitamin D Supplementation on Cardiovascular Disease in the Vitamin D Assessment Study: A Randomized Clinical Trial. JAMA Cardiol. 2017;2(6):608-616JAMA Cardiology (PubMed 28384800)
- Vitamin D Supplementation and Cardiovascular Disease Risks in More Than 83 000 Individuals in 21 Randomized Clinical Trials: A Meta-analysis. JAMA Cardiol. 2019;4(8):765-776JAMA Cardiology (PubMed 31215980)
- Vitamin D for the Prevention of Disease: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2024;109(8):1907-1947Journal of Clinical Endocrinology & Metabolism (PubMed 38828931)
- Vitamin D: Fact Sheet for Health ProfessionalsNIH Office of Dietary Supplements
- Complementary medicinesSAHPRA
- Complementary medicines: health supplements safety and efficacySAHPRA